Psychedelic Drugs Market By Drug Type (Psilocybin, Lysergic acid diethylamide, Ketamine, Dimethyltryptamine, Others), By Application (Depression & Anxiety, Post-Traumatic Stress Disorder, Addiction Treatment, Chronic Pain, Others), By Source (Natural Psychedelics, Synthetic Psychedelics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-user (Hospitals & Clinics, Research Institutions, Specialty Centers, Homecare Settings, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Psychedelic Drugs Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising mental health disorders demand alternative, effective treatments beyond conventional antidepressants.

3.2.2. Increasing clinical trials and FDA designations for psychedelic therapies drive industry growth.

3.2.3. Growing public and medical acceptance of psychedelics as therapeutic agents fuels market expansion.

3.3. Key industry pitfalls & challenges

3.3.1. Regulatory hurdles and classification of psychedelics as controlled substances restrict market progression.

3.3.2. Limited long-term safety data and lack of standardized treatment protocols raise concerns.

3.3.3. High cost of clinical development and therapy delivery affects widespread adoption.

3.4. Market Opportunities

3.4.1. Expansion into treatment-resistant depression and PTSD presents significant commercial potential.

3.4.2. Collaborations between biotech firms and academic institutions accelerate innovation and approval pathways.

3.4.3. Integration of digital therapeutics with psychedelic therapy offers enhanced patient monitoring and personalization.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Psychedelic Drugs Market, Drug Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Psilocybin

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Lysergic acid diethylamide

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Ketamine

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Dimethyltryptamine

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Others

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Psychedelic Drugs Market, Application Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Application, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Depression & Anxiety

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Post-Traumatic Stress Disorder

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Addiction Treatment

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Chronic Pain

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Others

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Psychedelic Drugs Market, Source Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Source, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Natural Psychedelics

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Synthetic Psychedelics

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Psychedelic Drugs Market, Distribution Channel Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Distribution Channel, 2025 & 2035

7.2. Hospital Pharmacies

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Retail Pharmacies

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Online Pharmacies

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Psychedelic Drugs Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals & Clinics

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Research Institutions

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Specialty Centers

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Homecare Settings

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.6. Others

8.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Psychedelic Drugs Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Drug Type, 2025-2035

9.2.3. North America Market Revenue, By Application, 2025-2035

9.2.4. North America Market Revenue, By Source, 2025-2035

9.2.5. North America Market Revenue, By Distribution Channel, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Drug Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Application, 2025-2035

9.2.7.3. U.S. Market Revenue, By Source, 2025-2035

9.2.7.4. U.S. Market Revenue, By Distribution Channel, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Drug Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Application, 2025-2035

9.2.8.3. Canada Market Revenue, By Source, 2025-2035

9.2.8.4. Canada Market Revenue, By Distribution Channel, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Drug Type, 2025-2035

9.3.3. Europe Market Revenue, By Application, 2025-2035

9.3.4. Europe Market Revenue, By Source, 2025-2035

9.3.5. Europe Market Revenue, By Distribution Channel, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Drug Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Application, 2025-2035

9.3.7.3. Germany Market Revenue, By Source, 2025-2035

9.3.7.4. Germany Market Revenue, By Distribution Channel, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Drug Type, 2025-2035

9.3.8.2. France Market Revenue, By Application, 2025-2035

9.3.8.3. France Market Revenue, By Source, 2025-2035

9.3.8.4. France Market Revenue, By Distribution Channel, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Drug Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Application, 2025-2035

9.3.9.3. U.K. Market Revenue, By Source, 2025-2035

9.3.9.4. U.K. Market Revenue, By Distribution Channel, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Drug Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Application, 2025-2035

9.3.10.3. Italy Market Revenue, By Source, 2025-2035

9.3.10.4. Italy Market Revenue, By Distribution Channel, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Drug Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Application, 2025-2035

9.3.11.3. Spain Market Revenue, By Source, 2025-2035

9.3.11.4. Spain Market Revenue, By Distribution Channel, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Drug Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Application, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Source, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Distribution Channel, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Application, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Source, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Drug Type, 2025-2035

9.4.7.2. China Market Revenue, By Application, 2025-2035

9.4.7.3. China Market Revenue, By Source, 2025-2035

9.4.7.4. China Market Revenue, By Distribution Channel, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Drug Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Application, 2025-2035

9.4.8.3. Japan Market Revenue, By Source, 2025-2035

9.4.8.4. Japan Market Revenue, By Distribution Channel, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Drug Type, 2025-2035

9.4.9.2. India Market Revenue, By Application, 2025-2035

9.4.9.3. India Market Revenue, By Source, 2025-2035

9.4.9.4. India Market Revenue, By Distribution Channel, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Drug Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Application, 2025-2035

9.4.10.3. Australia Market Revenue, By Source, 2025-2035

9.4.10.4. Australia Market Revenue, By Distribution Channel, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Drug Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Application, 2025-2035

9.4.11.3. South Korea Market Revenue, By Source, 2025-2035

9.4.11.4. South Korea Market Revenue, By Distribution Channel, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Drug Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Application, 2025-2035

9.4.12.3. Singapore Market Revenue, By Source, 2025-2035

9.4.12.4. Singapore Market Revenue, By Distribution Channel, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Source, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Drug Type, 2025-2035

9.5.3. Latin America Market Revenue, By Application, 2025-2035

9.5.4. Latin America Market Revenue, By Source, 2025-2035

9.5.5. Latin America Market Revenue, By Distribution Channel, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Drug Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Application, 2025-2035

9.5.7.3. Brazil Market Revenue, By Source, 2025-2035

9.5.7.4. Brazil Market Revenue, By Distribution Channel, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Drug Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Application, 2025-2035

9.5.8.3. Argentina Market Revenue, By Source, 2025-2035

9.5.8.4. Argentina Market Revenue, By Distribution Channel, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Drug Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Application, 2025-2035

9.5.9.3. Mexico Market Revenue, By Source, 2025-2035

9.5.9.4. Mexico Market Revenue, By Distribution Channel, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Drug Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Application, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Source, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Distribution Channel, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Drug Type, 2025-2035

9.6.3. MEA Market Revenue, By Application, 2025-2035

9.6.4. MEA Market Revenue, By Source, 2025-2035

9.6.5. MEA Market Revenue, By Distribution Channel, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Drug Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Application, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Source, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Distribution Channel, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Drug Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Application, 2025-2035

9.6.8.3. South Africa Market Revenue, By Source, 2025-2035

9.6.8.4. South Africa Market Revenue, By Distribution Channel, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Drug Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Source, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Distribution Channel, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Compass Pathways plc

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. MindMed Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. ATAI Life Sciences AG

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Cybin Inc.

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Field Trip Health Ltd.

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. GH Research PLC

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Numinus Wellness Inc.

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Seelos Therapeutics, Inc.

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Beckley Psytech Ltd.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. MAPS Public Benefit Corporation (MAPS PBC)

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Delix Therapeutics

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Small Pharma Inc.

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Entheon Biomedical Corp.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Revive Therapeutics Ltd.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Terran Biosciences, Inc.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis